Why dose escalation is slow
GLP-1 receptor agonists are dose-escalated over 4–6 months rather than started at the maintenance dose, for one main reason: GI tolerance. The dominant side effects — nausea, vomiting, diarrhea, constipation — are most pronounced during dose increases and largely attenuate within 2–3 weeks at any given dose.
Starting at the maintenance dose would produce severe GI symptoms in a majority of patients and high discontinuation rates. The slow ladder gives the gut time to adapt to each step and improves long-term tolerability.
Tirzepatide: 2.5 → 15 mg over 24 weeks
The standard tirzepatide titration schedule, per FDA labeling for both Mounjaro and Zepbound:
• Weeks 1–4: 2.5 mg weekly (initiation dose; not therapeutic) • Weeks 5–8: 5 mg weekly • Weeks 9–12: 7.5 mg weekly • Weeks 13–16: 10 mg weekly • Weeks 17–20: 12.5 mg weekly • Week 21+: 15 mg weekly (maintenance)
Some patients reach their effective dose at 7.5 or 10 mg and don't need to climb further. Others tolerate 15 mg well and stay there. The maintenance dose is set by clinical effect and tolerability, not a fixed target.
Semaglutide: 0.25 → 2.4 mg over ~16 weeks (obesity dose)
The Wegovy (semaglutide for obesity) titration schedule:
• Weeks 1–4: 0.25 mg weekly • Weeks 5–8: 0.5 mg weekly • Weeks 9–12: 1.0 mg weekly • Weeks 13–16: 1.7 mg weekly • Week 17+: 2.4 mg weekly (maintenance)
For Ozempic (semaglutide for T2D), maintenance doses are typically 0.5, 1.0, or 2.0 mg weekly depending on glycemic response.
Pause-and-step-back
If symptoms at a given dose persist beyond 2–3 weeks and meaningfully impair daily function, the right move is usually to stay at the current dose for another 4 weeks before re-attempting escalation — or to step back one level.
There is no clinical advantage to rushing through the ladder. Reaching maintenance dose three months later than the standard schedule with good tolerance is a meaningfully better outcome than reaching it on schedule but discontinuing therapy because of intolerable GI symptoms.